On Dec. 19, the Food and Drug Administration (FDA) approved Rubraca (rucaparib) to treat women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have the gene mutation deleterious BRCA as identified by an FDA-approved companion diagnostic test. Read more.
© 2019 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder